The stock of SELLAS Life Sciences Group Inc (SLS) has seen a -0.39% decrease in the past week, with a 19.34% gain in the past month, and a -0.39% decrease in the past quarter. The volatility ratio for the week is 7.98%, and the volatility levels for the past 30 days are at 17.02% for SLS. The simple moving average for the past 20 days is -3.15% for SLS’s stock, with a 3.89% simple moving average for the past 200 days.
Is It Worth Investing in SELLAS Life Sciences Group Inc (NASDAQ: SLS) Right Now?
The stock has a 36-month beta value of 2.39. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLS is 76.95M, and at present, short sellers hold a 12.74% of that float. On February 19, 2025, the average trading volume of SLS was 2.81M shares.
SLS) stock’s latest price update
The stock of SELLAS Life Sciences Group Inc (NASDAQ: SLS) has decreased by -0.39 when compared to last closing price of 1.27.Despite this, the company has seen a loss of -0.39% in its stock price over the last five trading days. globenewswire.com reported 2025-01-28 that NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 19,685,040 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 19,685,040 shares of common stock in a registered direct offering (the “Offering”) at a combined purchase price of $1.27 per share and accompanying warrant, priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $1.20 per share, will be immediately exercisable upon issuance and will expire 5 years from issuance.
Analysts’ Opinion of SLS
Many brokerage firms have already submitted their reports for SLS stocks, with Cantor Fitzgerald repeating the rating for SLS by listing it as a “Overweight.” The predicted price for SLS in the upcoming period, according to Cantor Fitzgerald is $18 based on the research report published on July 21, 2021 of the previous year 2021.
H.C. Wainwright gave a rating of “Buy” to SLS, setting the target price at $11 in the report published on April 02nd of the previous year.
SLS Trading at 13.79% from the 50-Day Moving Average
After a stumble in the market that brought SLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.25% of loss for the given period.
Volatility was left at 17.02%, however, over the last 30 days, the volatility rate increased by 7.98%, as shares surge +8.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.39% upper at present.
During the last 5 trading sessions, SLS fell by -1.77%, which changed the moving average for the period of 200-days by -2.54% in comparison to the 20-day moving average, which settled at $1.3053. In addition, SELLAS Life Sciences Group Inc saw 21.63% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SLS
The total capital return value is set at -2.06. Equity return is now at value -535.10, with -186.64 for asset returns.
Based on SELLAS Life Sciences Group Inc (SLS), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -57.42.
Currently, EBITDA for the company is 0.53 million with net debt to EBITDA at 1.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.26.
Conclusion
To sum up, SELLAS Life Sciences Group Inc (SLS) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
